TB-500 is in stock at Australian Peptides and available for immediate domestic dispatch across Australia this March 2026. For researchers who have previously sourced this compound from overseas, domestic availability means no customs delays, no cold-chain uncertainty, and no waiting.

What Is TB-500?

TB-500 is a synthetic peptide analogue of Thymosin Beta-4, a naturally occurring protein found in virtually all human and animal cells. Thymosin Beta-4 was first identified in the thymus gland, though subsequent research established that it is expressed widely across tissue types throughout the body.

The TB-500 peptide corresponds to the active region of Thymosin Beta-4 — specifically the actin-binding domain — which is understood to be responsible for much of the protein’s biological activity in research contexts. By isolating this region, TB-500 allows researchers to investigate the mechanisms of Thymosin Beta-4 in a more targeted way.

Areas of Research Interest

TB-500 has been the subject of research across several areas:

• Actin regulation — Thymosin Beta-4 is one of the most abundant actin-sequestering peptides in mammalian cells. TB-500 research has examined its role in modulating actin dynamics, which underpin a wide range of cellular functions including migration, division, and morphology
• Tissue repair and wound healing — a significant body of research has investigated TB-500 in tissue repair contexts, including skin, cardiac, and corneal tissue models
• Angiogenesis — research has explored TB-500’s potential role in blood vessel formation, with studies examining its interaction with endothelial cell migration
• Anti-inflammatory pathways — TB-500 has been investigated for interactions with inflammatory signalling, including downregulation of inflammatory cytokines in certain research models
• Cardiac research — some of the more recent literature has focused on TB-500 in cardiac tissue contexts, examining potential protective effects in heart muscle research models

TB-500 and BPC-157

TB-500 is one of the most frequently co-researched peptides alongside BPC-157. The two compounds have overlapping but distinct research profiles — BPC-157 is more associated with gastrointestinal and tendon research, while TB-500’s actin-binding mechanism gives it a different primary research focus. Both are consistently in stock at Australian Peptides.

March 2026: TB-500 Stock Update

TB-500 is fully in stock as of March 2026, available in research-appropriate vial sizes with batch documentation available on request. Domestic dispatch within 24 hours of order placement.

Why Source From Australian Peptides?

• Domestic Australian stock — no customs delays or international shipping risk
• 24-hour dispatch across Australia
• Research-grade quality with batch documentation on request
• Cold-chain compliant packaging for transit integrity
• Australian-based support team

Buy TB-500 Now

TB-500 is in stock and dispatching within 24 hours. Shop now at australianpeptides.com.